Previous 10 | Next 10 |
Poster published today at the 2021 American Association for Cancer Research (AACR) Annual Meeting shows the GP2 final 5 year immune response data from the Phase IIb clinical trial, concluding that GP2 immunotherapy generated GP2-specific immune responses leading to promising clinical ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to close at record levels Friday, with the Dow Jones hitting 33,800 and the S&P 500 topping 4,100, as investors ignored co...
Could These Biotech Stocks Be The Best Stocks To Invest In Right Now? You can’t deny that biotech stocks have and continue to receive a whole lot of attention from investors now. Accordingly, this is because of the current pandemic where biotech companies are continuously...
Shares of Greenwich LifeSciences (NASDAQ: GLSI) were rising 4.3% higher as of 11:41 a.m. EDT on Friday after soaring as much as 38.2% earlier in the day. The gain came following the company's announcement of positive results from a phase 2b study evaluating immunotherapy GP2 in trea...
Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...
Greenwich LifeSciences (GLSI) announces the abstract results of the final 5 year immune response data of the Phase IIb clinical trial in metastatic breast cancer recurrences at the 2021 AACR Annual Meeting.Potent immune response data supports the previously reported clinical outcome...
Abstract published today at the American Association for Cancer Research (AACR) Annual Meeting shows the GP2 final 5 year immune response data from the Phase IIb clinical trial. Poster showing graphs of immune response data over time will be published by AACR on Saturday, April 10...
Biotech Penny Stocks To Watch This Month Are you making a list of penny stocks for the month? You might want to have some biotech names on it. This has become one of the most active sectors traders have put money in this year and for a good reason. Aside from the obvious implications th...
SOS (SOS) +36%.Titan Medical (TMDI) +25%.CBAK Energy Technology (CBAT) +21%.Altimeter Growth (AGCUU) +18%.CA Healthcare Acquisition (CAHCU) +16%.TransMedics (TMDX) +16%. as FDA Advisory Panel has issued a favorable vote in support of approval of the OCS Heart System.Altimeter Growth (AGC...
Gainers: Scienjoy (SJ) +48%.Second Sight Medical Products (EYES) +36%.Greenwich LifeSciences (GLSI) +32%.Brooklyn ImmunoTherapeutics (BTX) +31%.Romeo Power (RMO) +28%.Target Hospitality (TH) +27%.BBQ Holdings (BBQ) +27%.SELLAS Life Sciences (SLS) +22%.GT Biopharma (GT...
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
Greenwich LifeSciences Inc. Website:
2024-07-11 21:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, tod...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...